volume 40 issue 1 pages 20-33

Macrophages in Atherosclerosis Regression

Publication typeJournal Article
Publication date2019-11-14
scimago Q1
wos Q1
SJR2.532
CiteScore12.9
Impact factor7.4
ISSN10795642, 15244636
Cardiology and Cardiovascular Medicine
Abstract

Macrophages play a central role in the development of atherosclerotic cardiovascular disease (ASCVD), which encompasses coronary artery disease, peripheral artery disease, cerebrovascular disease, and aortic atherosclerosis. In each vascular bed, macrophages contribute to the maintenance of the local inflammatory response, propagate plaque development, and promote thrombosis. These central roles, coupled with their plasticity, makes macrophages attractive therapeutic targets in stemming the development of and stabilizing existing atherosclerosis. In the context of ASCVD, classically activated M1 macrophages initiate and sustain inflammation, and alternatively activated M2 macrophages resolve inflammation. However, this classification is now considered an oversimplification, and a greater understanding of plaque macrophage physiology in ASCVD is required to aid in the development of therapeutics to promote ASCVD regression. Reviewed herein are the macrophage phenotypes and molecular regulators characteristic of ASCVD regression, and the current murine models of ASCVD regression.

Found 
Found 

Top-30

Journals

5
10
15
20
25
30
International Journal of Molecular Sciences
26 publications, 5.26%
Frontiers in Immunology
18 publications, 3.64%
Frontiers in Cardiovascular Medicine
17 publications, 3.44%
Frontiers in Pharmacology
11 publications, 2.23%
Arteriosclerosis, Thrombosis, and Vascular Biology
11 publications, 2.23%
Biomedicines
8 publications, 1.62%
Scientific Reports
8 publications, 1.62%
Cardiovascular Research
7 publications, 1.42%
Circulation Research
6 publications, 1.21%
Biomolecules
6 publications, 1.21%
Journal of Ethnopharmacology
6 publications, 1.21%
Advanced Science
6 publications, 1.21%
Cells
5 publications, 1.01%
International Immunopharmacology
5 publications, 1.01%
PLoS ONE
5 publications, 1.01%
Pharmacological Research
4 publications, 0.81%
Atherosclerosis
4 publications, 0.81%
Experimental Cell Research
4 publications, 0.81%
Biochemical and Biophysical Research Communications
4 publications, 0.81%
Redox Biology
4 publications, 0.81%
Life Sciences
4 publications, 0.81%
Experimental and Therapeutic Medicine
3 publications, 0.61%
Frontiers in Physiology
3 publications, 0.61%
Cell Death and Disease
3 publications, 0.61%
Inflammation
3 publications, 0.61%
Journal of Nanobiotechnology
3 publications, 0.61%
Biomedicine and Pharmacotherapy
3 publications, 0.61%
FASEB Journal
3 publications, 0.61%
Advanced healthcare materials
3 publications, 0.61%
5
10
15
20
25
30

Publishers

20
40
60
80
100
120
140
Elsevier
122 publications, 24.7%
Springer Nature
79 publications, 15.99%
MDPI
67 publications, 13.56%
Frontiers Media S.A.
57 publications, 11.54%
Ovid Technologies (Wolters Kluwer Health)
30 publications, 6.07%
Wiley
30 publications, 6.07%
Taylor & Francis
16 publications, 3.24%
Oxford University Press
14 publications, 2.83%
American Chemical Society (ACS)
13 publications, 2.63%
Cold Spring Harbor Laboratory
8 publications, 1.62%
Hindawi Limited
6 publications, 1.21%
Public Library of Science (PLoS)
5 publications, 1.01%
Spandidos Publications
4 publications, 0.81%
American Physiological Society
3 publications, 0.61%
SAGE
3 publications, 0.61%
Impact Journals
2 publications, 0.4%
Mary Ann Liebert
2 publications, 0.4%
AME Publishing Company
2 publications, 0.4%
American Society for Microbiology
2 publications, 0.4%
Hans Publishers
2 publications, 0.4%
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 0.4%
American Society for Clinical Investigation
1 publication, 0.2%
Bentham Science Publishers Ltd.
1 publication, 0.2%
Portland Press
1 publication, 0.2%
Korean Society of Industrial Engineering Chemistry
1 publication, 0.2%
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 0.2%
Royal Society of Chemistry (RSC)
1 publication, 0.2%
Walter de Gruyter
1 publication, 0.2%
American Association for the Advancement of Science (AAAS)
1 publication, 0.2%
20
40
60
80
100
120
140
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
495
Share
Cite this
GOST |
Cite this
GOST Copy
Berger J. S. Macrophages in Atherosclerosis Regression // Arteriosclerosis, Thrombosis, and Vascular Biology. 2019. Vol. 40. No. 1. pp. 20-33.
GOST all authors (up to 50) Copy
Berger J. S. Macrophages in Atherosclerosis Regression // Arteriosclerosis, Thrombosis, and Vascular Biology. 2019. Vol. 40. No. 1. pp. 20-33.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1161/ATVBAHA.119.312802
UR - https://doi.org/10.1161/ATVBAHA.119.312802
TI - Macrophages in Atherosclerosis Regression
T2 - Arteriosclerosis, Thrombosis, and Vascular Biology
AU - Berger, Jeffrey S.
PY - 2019
DA - 2019/11/14
PB - Ovid Technologies (Wolters Kluwer Health)
SP - 20-33
IS - 1
VL - 40
PMID - 31722535
SN - 1079-5642
SN - 1524-4636
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2019_Berger,
author = {Jeffrey S. Berger},
title = {Macrophages in Atherosclerosis Regression},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2019},
volume = {40},
publisher = {Ovid Technologies (Wolters Kluwer Health)},
month = {nov},
url = {https://doi.org/10.1161/ATVBAHA.119.312802},
number = {1},
pages = {20--33},
doi = {10.1161/ATVBAHA.119.312802}
}
MLA
Cite this
MLA Copy
Berger, Jeffrey S.. “Macrophages in Atherosclerosis Regression.” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 40, no. 1, Nov. 2019, pp. 20-33. https://doi.org/10.1161/ATVBAHA.119.312802.